Skip to main content
GeneOne Life Science, Inc. logo

GeneOne Life Science, Inc. — Investor Relations & Filings

Ticker · 011000 ISIN · KR7011000007 KO Professional, scientific and technical activities
Open in API
Filings indexed 490 across all filing types
Latest filing 2026-06-01 Governance Information
Country KR South Korea
Listing KO 011000

About GeneOne Life Science, Inc.

https://www.genels.com/en/

GeneOne Life Science, Inc. is a biopharmaceutical research and development company specializing in nucleic acid-based biomedicines. The company's core focus is on developing DNA and mRNA vaccines, particularly for emerging infectious diseases, leveraging its rapid development platforms. In therapeutics, GeneOne utilizes a proprietary DNA plasmid delivery technology to enable the expression of recombinant proteins and plasmid-encoded monoclonal antibodies (Plas-mAbs®). This non-viral vector approach is designed to offer a safer and more cost-effective alternative to traditional gene therapies and cell-line derived monoclonal antibody treatments for conditions such as cancers and autoimmune disorders. The company also develops immunomodulatory small molecule drugs. Through its subsidiary, GeneOne possesses cGMP-grade manufacturing capabilities for DNA plasmids, supporting its internal pipeline and contract manufacturing services.

Recent filings

Filing Released Lang Actions
기업지배구조보고서공시
Governance Information Classification · 90% confidence The document is a detailed corporate governance report (“기업지배구조 보고서”) laying out the company’s governance policies, board composition, committees, shareholder meeting practices, and internal controls. It is not merely an announcement or proxy statement, but a comprehensive governance disclosure. This corresponds to the Governance Information category.
2026-06-01 Korean
[기재정정]주요사항보고서(자기전환사채매도결정)
Capital/Financing Update Classification · 85% confidence The document is a correction (“정정신고”) to a previously filed “주요사항보고서” (Major Event Report) regarding the company’s decision to sell self‐converted bonds – a financing transaction affecting the capital structure. This falls squarely under updates on corporate fundraising or financing activities, matching the Capital/Financing Update category.
2026-05-29 Korean
[기재정정]주요사항보고서(감자결정)
Share Issue/Capital Change Classification · 90% confidence The document is a Korean "주요사항보고서(감자 결정) 정정신고", a regulatory major‐event filing to the Korean Financial Supervisory Service and stock exchange announcing and correcting details of a capital reduction (share combination) schedule. This is not an AGM presentation, earnings release, or annual/interim report, but rather an announcement of capital structure change. It therefore falls under Share Issue/Capital Change (SHA).
2026-05-26 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 91% confidence The document is a full convocation notice (“주주총회 소집공고”) for the 51st Extraordinary Shareholders’ Meeting, including detailed agenda items (articles amendment, director elections, capital reduction), meeting date, venue, and attachments. It is not an earnings release, financial report, or results announcement but rather materials provided to shareholders to inform them of, request their attendance at, and solicit votes for the meeting. Under our taxonomy this corresponds to a Proxy Solicitation & Information Statement.
2026-05-26 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed proxy solicitation information statement (“의결권대리행사 권유 참고자료”) for the company’s 51st extraordinary shareholder meeting, including agenda items, dates, proxy procedures, director candidate info, and capital reduction/charter amendments. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-26 Korean
[기재정정]주주총회소집결의
Regulatory Filings Classification · 83% confidence The document is a Korean disclosure titled “주주총회소집결의” (resolution to convene a shareholders’ meeting) with corrected meeting date and agenda items. It is not the full annual or interim report itself, nor an earnings release, proxy statement (US-focused), or dividend notice. Rather, it is a regulatory announcement of a shareholders’ meeting convening. There is no dedicated category for a meeting notice, so it falls under general Regulatory Filings (RNS).
2026-05-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.